Unconventional Myosin-XVIIIa / CD245 (MYO18A) Antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Unconventional Myosin-XVIIIa / CD245 (MYO18A) Antibody is a Unconjugated-conjugated Mouse Monoclonal antibody for Unconventional Myosin-XVIIIa / CD245 (MYO18A).
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Unconventional Myosin-XVIIIa / CD245 (MYO18A) |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | FCM: 1-5 μg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Purification | Purified by protein-A affinity chromatography. |
| Size 1 | 0.1 mg |
| Tested Applications | WB, IHC, FCM, IP |
| Buffer | PBS, pH 7.4, 15 mM sodium azide. |
| Availability | Shipped within 5-12 working days. |
| Storage | Store at 2-8°C. Do not freeze. |
| Dry Ice | No |
| Background | Antibody anti-MYO18A |
| Status | RUO |
| Note | Concentration: 1 mg/ml - |
Descripción
Related Products
MYO18A antibody
May link Golgi membranes to the cytoskeleton and participate in the tensile force required for vesicle budding from the Golgi. Thereby, may play a role in Golgi membrane trafficking and could indirectly give its flattened shape to the Golgi apparatus. Alternatively, in concert with LURAP1 and CDC42BPA/CDC42BPB, has been involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration. May be involved in the maintenance of the stromal cell architectures required for cell to cell contact.
Ver ProductoMYO18A antibody
Inhibits the cytotoxic effects of TNF-alpha and overexpressed TNF receptor adapters TRADD, FADD, and RIPK1. Involved in TGF-beta1 inhibition of IkappaB-alpha expression and suppression of TNF-mediated IkappaB-alpha degradation.
Ver Producto